Literature DB >> 29181551

[Metabolic disorders as paraneoplastic syndromes].

S Krug1, P Michl2.   

Abstract

Paraneoplastic syndromes are characterized by the tumor-induced release of peptide hormones and/or the initiation of immune phenomena, which elicit clinical changes and alterations in laboratory parameters independent of the tumor size and spread. In addition to neurological, endocrinal and rheumatological phenotypes, metabolic alterations play a special role in the clinical routine as they commonly present with acute symptoms in an emergency situation and necessitate immediate diagnosis and prompt initiation of treatment. Metabolic alterations within the framework of malignant diseases should be treated in a multidisciplinary team and it is often necessary to perform monitoring and treatment in an intensive care unit. This article focuses on the diagnostic and therapeutic options for metabolic disorders due to paraneoplastic syndromes, such as hypercalcemia, hypocalcemia, hyperglycemia, hypoglycemia and a special variant of tumor-induced metabolic disorders due to tumor lysis syndrome.

Entities:  

Keywords:  Hypercalcemia; Hypoglycemia; Pancreatic neoplasms; Parathyroid hormone-related protein; Tumor lysis syndrome

Mesh:

Substances:

Year:  2018        PMID: 29181551     DOI: 10.1007/s00108-017-0357-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  82 in total

1.  Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia.

Authors:  Yusuf Açıkgöz; Mehmet Ali Nahit Sendur; Nuriye Yıldırım Ozdemir; Sercan Aksoy; Dogan Uncu; Nurullah Zengin
Journal:  J Craniomaxillofac Surg       Date:  2013-11-15       Impact factor: 2.078

2.  Rehydration in the treatment of severe hypercalcaemia.

Authors:  D J Hosking; A Cowley; C A Bucknall
Journal:  Q J Med       Date:  1981

3.  Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect.

Authors:  Maya Ignaszewski; Patrick Kohlitz
Journal:  Am J Emerg Med       Date:  2017-05-26       Impact factor: 2.469

Review 4.  Salmon calcitonin in the acute management of hypercalcemia.

Authors:  L A Wisneski
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

5.  Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature.

Authors:  L W J Baijens; J J Manni
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-06-29       Impact factor: 2.503

6.  Hypoglycemia Observed on Continuous Glucose Monitoring Associated With IGF-2-Producing Solitary Fibrous Tumor.

Authors:  Sonoko Otake; Takuma Kikkawa; Miho Takizawa; Junko Oya; Ko Hanai; Nobue Tanaka; Junnosuke Miura; Izumi Fukuda; Masato Kanzaki; Tatsuo Sawada; Naomi Hizuka; Takamasa Onuki; Yasuko Uchigata
Journal:  J Clin Endocrinol Metab       Date:  2015-04-27       Impact factor: 5.958

7.  Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence.

Authors:  M S Soyfoo; K Brenner; M Paesmans; J J Body
Journal:  Support Care Cancer       Date:  2012-12-11       Impact factor: 3.603

Review 8.  Differential diagnosis of hypercalcemia.

Authors:  F W Lafferty
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

Review 9.  Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.

Authors:  Bertrand Coiffier; Arnold Altman; Ching-Hon Pui; Anas Younes; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

10.  Denosumab for treatment of hypercalcemia of malignancy.

Authors:  Mimi I Hu; Ilya G Glezerman; Sophie Leboulleux; Karl Insogna; Rasim Gucalp; Waldemar Misiorowski; Bennett Yu; Paul Zorsky; Diego Tosi; Alberto Bessudo; Arnaud Jaccard; Giuseppe Tonini; Wendy Ying; Ada Braun; Rajul K Jain
Journal:  J Clin Endocrinol Metab       Date:  2014-06-10       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.